- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07618676
The 50:50 Nitrous Oxide vs 2% Lidocaine Challenge
25. maj 2026 opdateret af: Ana Cvetković, Institute for Oncology and Radiology of Serbia
The 50:50 Nitrous Oxide Challenge: A Prospective Randomised Trial - Needle, Meet Your Match
The main goal of the project is to assess pain levels and patient comfort during the administration of a 50:50 Nitrous Oxide/Oxygen gas mixture, in comparison to the same parameters under the standard method used at our institution, which includes injecting a local anaesthetic at the site of planned puncture for central venous catheterisation.
Studieoversigt
Status
Rekruttering
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
62
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Ana Cvetkovic, MD,PhD
- Telefonnummer: +381 11 2067 100
- E-mail: ana.cvetkovic@ncrc.ac.rs
Studiesteder
-
-
Savski Venac
-
Belgrade, Savski Venac, Serbien, 11000
- Rekruttering
- Institute for Oncology and Radiology of Serbia
-
Kontakt:
- Ana Cvetković, MD, PhD
- Telefonnummer: +381 11 2067 100
- E-mail: ana.cvetkovic@ncrc.ac.rs
-
Kontakt:
- Andrej Jokić, MD
- Telefonnummer: +381 11 2067 100
- E-mail: anestezija@ncrc.ac.rs
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Subjects who have not previously received Nitrous Oxide.
- Subjects of both sexes, aged between 18 and 65 inclusive.
- Subjects who have signed informed consent with full disclosure; no study-related procedure may begin until the subject signs the consent form.
Exclusion Criteria:
- Infection at the planned puncture site.
- Pregnancy.
- Intracranial hypertension.
- Vitamin B12 deficiency.
- Hemodynamic instability.
- BMI over 35.
- Glasgow Coma Scale (GCS) score less than 15.
- Presence of chronic pain.
- Neurological disorders.
- Hematologic disorders.
- More than two attempts at venous puncture (Subject Withdrawal Criterion).
- Subject experienced an adverse event requiring early discontinuation (Subject Withdrawal Criterion).
- Withdrawal of consent by the subject (Subject Withdrawal Criterion)
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Nitrous Oxide Group
This will be the experimental group in which the patients will receive a mixture of gases to assess the efficacy of the treatment compared to the control.
|
After placing the patient in the appropriate supination + Trendelenburg position, the operative field (neck and subclavian region) is prepared using antiseptic measures.Five minutes before needle insertion, a mask connected to a 50:50 Nitrous Oxide/Oxygen cylinder with a flow rate of 6 liters per minute is placed on the patient's face and held by the patient.
The mask has a valve that opens only when the patient creates negative pressure during inhalation.The patient is instructed to breathe spontaneously; the mask is removed once the catheter is inserted into the target vein or after cessation of painful stimulation.
Andre navne:
|
|
Aktiv komparator: Lidocaine 2%
The control group receiving the standard of care for this intervention.
|
After placing the patient in the appropriate supination + Trendelenburg position, the operative field (neck and subclavian region) is prepared using antiseptic measures.
Then, under ultrasound control, the most favorable central vein for puncture is determined (v.
jugularis interna or v. subclavia) and a 25-gauge needle is used to infiltrate the skin and subcutaneous tissue above the selected vein with local anesthetic.
Five minutes after infiltration, puncture of the selected vein is performed using the Seldinger technique.
Continuous communication with the patient is maintained throughout the procedure.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain Intensity During Needle Insertion
Tidsramme: At the time of needle insertion
|
Assessed using a standard Numeric Rating Scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain).
Higher scores indicate greater pain intensity.
|
At the time of needle insertion
|
|
Pain Intensity During Catheter Placement
Tidsramme: During catheter placement
|
Assessed using a standard Numeric Rating Scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain).
Higher scores indicate greater pain intensity.
|
During catheter placement
|
|
Pain Intensity Post-Intervention
Tidsramme: 2 minutes after gas inhalation (Treatment 1) or 2 minutes post-intervention (Treatment 2)
|
Assessed using a standard Numeric Rating Scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain).
Higher scores indicate greater pain intensity.
|
2 minutes after gas inhalation (Treatment 1) or 2 minutes post-intervention (Treatment 2)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Patient Anxiety Score
Tidsramme: Post-intervention (at the conclusion of the central venous catheterization procedure)
|
Assessed using a standard Numeric Rating Scale (NRS) ranging from 0 (no anxiety) to 10 (worst imaginable anxiety).
Higher scores indicate greater anxiety levels.
|
Post-intervention (at the conclusion of the central venous catheterization procedure)
|
|
Patient Satisfaction Score
Tidsramme: Post-intervention (at the conclusion of the central venous catheterization procedure)
|
Assessed using a Numeric Rating Scale (NRS) where patients rate their overall satisfaction with the anesthetic method.
The scale ranges from 0 (completely unsatisfied) to 4 (completely satisfied).
Higher scores indicate greater satisfaction.
|
Post-intervention (at the conclusion of the central venous catheterization procedure)
|
|
Incidence of Treatment-Related Adverse Events
Tidsramme: From the start of the intervention through 30 minutes post-procedure
|
Percentage of participants experiencing specific adverse events, including nausea/vomiting, unpleasant dreams, paresthesias, dizziness, and euphoria, as recorded by subjective patient reports.
|
From the start of the intervention through 30 minutes post-procedure
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Ana Cvetković, MD, PhD, Institute for Oncology and Radiology of Serbia
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
6. juni 2025
Primær færdiggørelse (Anslået)
6. juni 2026
Studieafslutning (Anslået)
1. juli 2026
Datoer for studieregistrering
Først indsendt
25. maj 2026
Først indsendt, der opfyldte QC-kriterier
25. maj 2026
Først opslået (Faktiske)
1. juni 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
1. juni 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
25. maj 2026
Sidst verificeret
1. maj 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 01-1/2025/1264
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
IPD-planbeskrivelse
There is no current plan to share individual participant data to external registries.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Nitrous Oxide-Oxygen
-
McGill UniversityAktiv, ikke rekrutterendeKnoglesygdomme, metaboliske | Diætproteiner | Akut motionCanada
-
Traditional Alternative Medicine Research, IndiaAfsluttet
-
Traditional Alternative Medicine Research, IndiaAfsluttetHIV-infektionerIndien
-
Tufts UniversityNational Institute on Aging (NIA)AfsluttetMuskeltab | Aldersrelateret sarkopeniForenede Stater
-
I.M. Sechenov First Moscow State Medical UniversityAfsluttetAterosklerose i arterienDen Russiske Føderation
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)RekrutteringKroniske nyresygdommeForenede Stater
-
Stanford UniversityThe V Foundation for Cancer ResearchAfsluttetTilbagevendende hudkræft | Basalcellekarcinom i hudenForenede Stater
-
National Cancer Institute (NCI)AfsluttetTilbagevendende overgangscellekræft i nyrebækkenet og urinlederen | Overgangscellekarcinom i blæren | Ureterkræft | Tilbagevendende urinrørskræftForenede Stater
-
Stanford UniversityNational Cancer Institute (NCI)Trukket tilbageTilbagevendende akut myeloid leukæmi hos voksne | Akut megakaryoblastisk leukæmi hos voksne (M7) | Voksen akut minimalt differentieret myeloid leukæmi (M0) | Akut monoblastisk leukæmi hos voksne (M5a) | Akut monocytisk leukæmi hos voksne (M5b) | Voksen akut myeloblastisk leukæmi med modning (M2) | Voksen akut myeloblastisk leukæmi uden modning (M1) og andre forhold
-
National Cancer Institute (NCI)AfsluttetEkstranodal marginalzone B-celle lymfom i slimhinde-associeret lymfoidt væv | Nodal Marginal Zone B-celle lymfom | Tilbagevendende, diffust, småcellet lymfom hos voksne | Tilbagevendende grad 1 follikulært lymfom | Tilbagevendende grad 2 follikulært lymfom | Tilbagevendende marginalzone lymfom | Milt... og andre forholdForenede Stater